Target Name: MIR499A
NCBI ID: G574501
Review Report on MIR499A Target / Biomarker Content of Review Report on MIR499A Target / Biomarker
MIR499A
Other Name(s): hsa-mir-499 | hsa-miR-499a-5p | hsa-miR-499a-3p | hsa-mir-499a | MIRN499 | mir-499a | microRNA 499a | MicroRNA 499a | MIR499

MIR499A: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Chronic pain is a significant public health issue that affects millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50 million people are affected by chronic pain, with 20% of the population having chronic non-cancer pain and 30% having chronic cancer pain. Chronic pain can be caused by a variety of conditions, including musculoskeletal disorders, neuropathies, and psychiatric conditions. The management of chronic pain is a complex and multifaceted approach that requires a combination of medical, psychological, and social strategies.

MIR499A: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

MIR499A is a protein that is expressed in various tissues and organs, including the brain, spinal cord, and peripheral tissues. It is a member of the heat shock protein (HSP) family and has been shown to play a role in a variety of physiological processes, including stress response, inflammation, and neuroprotection. MIR499A has also been shown to be involved in pain signaling and may be a potential drug target for the treatment of chronic pain.

Potential Drug Target

MIR499A has been shown to interact with various molecules, including GABA, a neurotransmitter that has anti-inflammatory and anxiolytic effects. GABA is a known ligand for the N-methyl-D-aspartate (NMDA) receptor, which is a key mediator of pain signaling. MIR499A has been shown to modulate NMDA receptor function and may be a potential drug target for the treatment of chronic pain.

MIR499A has also been shown to interact with opioids, which are often used to treat chronic pain. The use of opioids can be problematic due to their potential for abuse and dependence. MIR499A may be a potential alternative to opioids for the treatment of chronic pain, as it has been shown to have similar analgesic effects without the potential for abuse and dependence.

Biomarker

MIR499A may also be a potential biomarker for the monitoring of chronic pain. The use of pain biomarkers, such as tissue samples or blood levels of certain molecules, can help to diagnose and monitor the severity and effectiveness of pain treatments. MIR499A may be a useful biomarker for the treatment of chronic pain due to its potential role in pain signaling and its interaction with GABA and opioids.

MIR499A has been shown to be expressed in various tissues and organs, including the brain, spinal cord, and peripheral tissues. It is a potential drug target for the treatment of chronic pain due to its interaction with GABA and opioids. Further research is needed to fully understand the role of MIR499A in pain signaling and its potential as a drug target for the treatment of chronic pain.

Conclusion

Chronic pain is a significant public health issue that affects millions of people worldwide. The management of chronic pain is a complex and multifaceted approach that requires a combination of medical, psychological, and social strategies. MIR499A may be a potential drug target and biomarker for the treatment of chronic pain due to its interaction with GABA and opioids. Further research is needed to fully understand the role of MIR499A in pain signaling and its potential as a drug target for the treatment of chronic pain.

Protein Name: MicroRNA 499a

The "MIR499A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR499A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR499B | MIR5000 | MIR5001 | MIR5002 | MIR5003 | MIR5004 | MIR5006 | MIR5007 | MIR5008 | MIR5009 | MIR500A | MIR500B | MIR501 | MIR5010 | MIR5011 | MIR502 | MIR503 | MIR503HG | MIR504 | MIR5047 | MIR505 | MIR506 | MIR507 | MIR508 | MIR5088 | MIR5089 | MIR509-1 | MIR509-2 | MIR509-3 | MIR5090 | MIR5091 | MIR5092 | MIR5093 | MIR5094 | MIR510 | MIR5100 | MIR511 | MIR511-2 | MIR512-1 | MIR512-2 | MIR513A1 | MIR513A2 | MIR513B | MIR513C | MIR514A1 | MIR514A2 | MIR514A3 | MIR514B | MIR515-1 | MIR515-2 | MIR516A1 | MIR516A2 | MIR516B1 | MIR516B2 | MIR517A | MIR517B | MIR517C | MIR5186 | MIR5187 | MIR5188 | MIR5189 | MIR518A1 | MIR518A2 | MIR518B | MIR518C | MIR518D | MIR518E | MIR518F | MIR5190 | MIR5191 | MIR5192 | MIR5193 | MIR5194 | MIR5195 | MIR5196 | MIR5197 | MIR519A1 | MIR519A2 | MIR519B | MIR519C | MIR519D | MIR519E | MIR520A | MIR520B | MIR520C | MIR520D | MIR520E | MIR520F | MIR520G | MIR520H | MIR521-1 | MIR521-2 | MIR522 | MIR523 | MIR524 | MIR525 | MIR526A1 | MIR526A2 | MIR526B | MIR527